ArticlePublic health challenges2025
Global Burden of Human Metapneumovirus: Bridging Gaps in Prevention, Diagnostics and Treatment.
Article in Public health challenges, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Spatiotemporal Dynamics of Human Metapneumovirus and Potential Impact of Respiratory Syncytial Virus Interventions in the United States.medRxiv : the preprint server for health sciences · 2026Article
- Mechanistic insights and emerging applications of human metapneumovirus (HMPV) treatment: From molecular design to translational immunity.Folia microbiologica · 2026Review
- Gut microbiota and serum metabolome in children with human metapneumovirus infection.Frontiers in immunology · 2026Article
- Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment.Viruses · 2025Review
- Human metapneumovirus: an emerging public health threat and harbinger of a new pandemic.GMS hygiene and infection control · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human metapneumovirus (hMPV) is a respiratory virus with a significant impact, particularly on the paediatric population, yet it remains an under-recognized contributor to respiratory infections globally. Recent epidemics in China, India and Europe underscore its clinical burden, with severe cases linked to bronchiolitis, pneumonia and exacerbations of chronic conditions. Despite its impact, hMPV remains underdiagnosed due to limited access to molecular diagnostics and routine surveillance, particularly in low- and middle-income countries. The absence of antivirals or vaccines exacerbates its public health challenge. Advances in multiplex diagnostics and vaccine development offer hope but require sustained global investment. Addressing gaps in prevention, diagnostics and treatment is critical to mitigating hMPV's growing threat and ensuring equitable healthcare outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.